Display options
Cite
Tran TN, Caspard H, Magrini F. Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open Access Rheumatol. 2013;5:21-32doi: 10.2147/OARRR.S40526.
Tran, T. N., Caspard, H., & Magrini, F. (2013). Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open access rheumatology : research and reviews, 521-32. https://doi.org/10.2147/OARRR.S40526
Tran, Trung N, et al. "Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature." Open access rheumatology : research and reviews vol. 5 (2013): 21-32. doi: https://doi.org/10.2147/OARRR.S40526
Tran TN, Caspard H, Magrini F. Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open Access Rheumatol. 2013 Mar 19;5:21-32. doi: 10.2147/OARRR.S40526. eCollection 2013. PMID: 27790021; PMCID: PMC5074790.
Copy Download .nbib Format: NLM
Share it on

Open Access Rheumatol. 2013 Mar 19;5:21-32. doi: 10.2147/OARRR.S40526. eCollection 2013.

Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.

Open access rheumatology : research and reviews

Trung N Tran, Herve Caspard, Fabio Magrini

Affiliations

  1. Clinical Development, MedImmune, Gaithersburg, MD, USA.
  2. Eli Lilly, San Diego, CA, USA.

PMID: 27790021 PMCID: PMC5074790 DOI: 10.2147/OARRR.S40526

Abstract

data on the incidence density (ie, incidence per person-year [PY]) of serious infection, opportunistic infection, and tuberculosis associated with each of the nine biologic therapies currently indicated in rheumatoid arthritis patients are not available. To summarize these data, a systematic review was conducted with searches on PubMed and Embase of literature ranging from January 1998 to November 2011. Incidence density was extracted and reported using the definitions from the respective publications. If the incidence density was not reported, estimation was made using available information. A total of 72 published studies met the inclusion criteria and were reviewed, including 44 clinical trials, open-label extension studies, or meta-analyses, and 28 observational studies. Additional calculation of the incidence density was performed in 12 studies for serious infection and in 13 studies for opportunistic infection or tuberculosis. The incidence of serious infection was consistent across studies and biologic therapies, ranging from 0 to 11/100 PY but mainly clustered from 2 to 6/100 PY. Fewer incidence data were available for opportunistic infection and tuberculosis. The incidence of opportunistic infection and tuberculosis ranged widely, from 0.01 to 3.0/100 PY and 0.01 to 2.6/100 PY, respectively. The data on serious infection may be used to evaluate the public health risk and benefit of biologic treatment. They may also serve as a point of reference for future studies. The limited data on opportunistic infection and the lack of a consistent definition of opportunistic infection invite caution for a benchmark rate for opportunistic infection as a composite category.

Keywords: DMARD; adverse event; biologic; infection; review; safety

References

  1. Lancet. 1999 Dec 4;354(9194):1932-9 - PubMed
  2. Arthritis Rheum. 2006 Aug;54(8):2368-76 - PubMed
  3. Arthritis Res Ther. 2010;12(2):R67 - PubMed
  4. Ann Rheum Dis. 2009 Oct;68(10 ):1580-4 - PubMed
  5. Clin Infect Dis. 2004 Oct 15;39(8):1254-5 - PubMed
  6. Arthritis Rheum. 2004 Feb;50(2):372-9 - PubMed
  7. Arthritis Rheum. 2010 Apr;62(4):917-28 - PubMed
  8. Arthritis Rheum. 2009 Aug;60(8):2272-83 - PubMed
  9. Arthritis Rheum. 2008 Nov;58(11):3319-29 - PubMed
  10. Medicine (Baltimore). 2011 Mar;90(2):139-45 - PubMed
  11. Ann Rheum Dis. 2008 Aug;67(8):1096-103 - PubMed
  12. Ann Rheum Dis. 2009 Jun;68(6):805-11 - PubMed
  13. J Rheumatol. 2011 Aug;38(8):1552-62 - PubMed
  14. Arthritis Care Res (Hoboken). 2011 Mar;63(3):373-82 - PubMed
  15. JAMA. 2006 May 17;295(19):2275-85 - PubMed
  16. Ann Rheum Dis. 2011 Aug;70(8):1401-6 - PubMed
  17. Lancet. 2008 Mar 22;371(9617):987-97 - PubMed
  18. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):679-85 - PubMed
  19. Ann Rheum Dis. 2009 Jun;68(6):797-804 - PubMed
  20. Ann Rheum Dis. 2007 Jun;66(6):732-9 - PubMed
  21. Arthritis Res Ther. 2010;12(3):R121 - PubMed
  22. J Rheumatol. 2006 May;33(5):854-61 - PubMed
  23. J Rheumatol. 2011 May;38(5):855-62 - PubMed
  24. Arthritis Rheum. 2007 Jun 15;57(5):756-61 - PubMed
  25. Ann Rheum Dis. 2009 Dec;68(12 ):1870-7 - PubMed
  26. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794 - PubMed
  27. Ann Rheum Dis. 2010 Sep;69(9):1629-35 - PubMed
  28. Ann Rheum Dis. 2006 Jun;65(6):753-9 - PubMed
  29. Ann Rheum Dis. 2011 Oct;70(10 ):1826-30 - PubMed
  30. Arthritis Rheum. 2005 Jul;52(7):1986-92 - PubMed
  31. Ann Rheum Dis. 2009 Dec;68(12):1863-9 - PubMed
  32. Arthritis Rheum. 2003 Nov;48(11):3013-22 - PubMed
  33. Rheumatology (Oxford). 2007 Jul;46(7):1157-60 - PubMed
  34. JAMA. 2011 Dec 7;306(21):2331-9 - PubMed
  35. Ann Rheum Dis. 2011 Apr;70(4):616-23 - PubMed
  36. Arthritis Rheum. 2008 Aug 15;59(8):1074-81 - PubMed
  37. Arthritis Rheum. 2006 Sep;54(9):2793-806 - PubMed
  38. Arthritis Rheum. 2011 Oct;63(10):2854-64 - PubMed
  39. Arthritis Rheum. 2008 Apr;58(4):964-75 - PubMed
  40. Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36 - PubMed
  41. Arthritis Rheum. 2004 May;50(5):1400-11 - PubMed
  42. Arthritis Rheum. 2005 Nov;52(11):3403-12 - PubMed
  43. Arthritis Rheum. 2004 Nov;50(11):3432-43 - PubMed
  44. Clin Exp Immunol. 2010 Jul 1;161(1):1-9 - PubMed
  45. N Engl J Med. 2001 Oct 11;345(15):1098-104 - PubMed
  46. Rheumatology (Oxford). 2011 Jan;50(1):222-9 - PubMed
  47. Arthritis Rheum. 2007 Dec;56(12):3896-908 - PubMed
  48. Rheumatology (Oxford). 2007 Jul;46(7):1122-5 - PubMed
  49. Ann Rheum Dis. 2010 Jun;69(6):1129-35 - PubMed
  50. Rheumatology (Oxford). 2007 Feb;46(2):327-34 - PubMed
  51. J Rheumatol. 2010 Mar;37(3):558-67 - PubMed
  52. Ann Rheum Dis. 2006 Aug;65(8):1006-12 - PubMed
  53. Arthritis Rheum. 2007 Mar 15;57(2):343-6 - PubMed
  54. Arthritis Rheum. 2008 Apr;58(4):953-63 - PubMed
  55. Semin Arthritis Rheum. 2010 Apr;39(5):327-46 - PubMed
  56. Ann Rheum Dis. 2010 Mar;69(3):522-8 - PubMed
  57. J Drugs Dermatol. 2011 Mar;10(3):289-300 - PubMed
  58. Ann Rheum Dis. 2010 Feb;69(2):380-6 - PubMed
  59. Ann Rheum Dis. 2009 Jul;68(7):1136-45 - PubMed
  60. Ann Rheum Dis. 2006 Jun;65(6):760-2 - PubMed
  61. Ann Rheum Dis. 2011 Nov;70(11):1914-20 - PubMed
  62. Rheumatology (Oxford). 2011 Jan;50(1):124-31 - PubMed
  63. Arthritis Rheum. 2003 Apr;48(4):927-34 - PubMed
  64. Arthritis Rheum. 2009 Jul;60(7):1884-94 - PubMed
  65. Arthritis Rheum. 2011 Mar;63(3):609-21 - PubMed
  66. Arthritis Res Ther. 2011;13(5):R141 - PubMed
  67. Arthritis Rheum. 2012 Feb;64(2):350-9 - PubMed
  68. Arthritis Rheum. 2007 Sep;56(9):2896-904 - PubMed
  69. Arthritis Rheum. 2002 Sep;46(9):2287-93 - PubMed
  70. Arthritis Rheum. 2006 Apr;54(4):1075-86 - PubMed
  71. Ann Rheum Dis. 2012 Feb;71(2):198-205 - PubMed
  72. J Rheumatol. 2011 Jul;38(7):1258-64 - PubMed
  73. Ann Rheum Dis. 2007 Oct;66(10):1339-44 - PubMed
  74. J Rheumatol. 2007 Apr;34(4):706-11 - PubMed
  75. Ann Rheum Dis. 2011 Nov;70(11):2003-7 - PubMed
  76. Mod Rheumatol. 2010 Jun;20(3):222-32 - PubMed
  77. Clin Exp Rheumatol. 2011 Mar-Apr;29(2):238-47 - PubMed
  78. Ann Rheum Dis. 2006 Jul;65(7):889-94 - PubMed
  79. Arthritis Rheum. 2002 Mar;46(3):614-24 - PubMed
  80. Autoimmun Rev. 2009 Jan;8(3):266-73 - PubMed
  81. Ann Rheum Dis. 2011 Dec;70(12 ):2148-51 - PubMed

Publication Types